These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 15939202)

  • 61. Interlaboratory comparison of behavioral testing.
    Butcher RE; Hoar RM; Nolan GA; Vorhees CV
    J Assoc Off Anal Chem; 1979 Jul; 62(4):840-3. PubMed ID: 500535
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Genotoxicity of nanomaterials: refining strategies and tests for hazard identification.
    Pfuhler S; Elespuru R; Aardema MJ; Doak SH; Maria Donner E; Honma M; Kirsch-Volders M; Landsiedel R; Manjanatha M; Singer T; Kim JH
    Environ Mol Mutagen; 2013 May; 54(4):229-39. PubMed ID: 23519787
    [TBL] [Abstract][Full Text] [Related]  

  • 63. An historical perspective on behavioral teratology.
    Butcher RE
    Neurobehav Toxicol Teratol; 1985; 7(6):537-40. PubMed ID: 3915056
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Prevention programs in the 21st century: what we do not discuss in public.
    Holder H
    Addiction; 2010 Apr; 105(4):578-81. PubMed ID: 19922518
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Animal models for human behavioral deficiencies during development.
    Elsner J
    Neurotoxicology; 1992; 13(1):65-76. PubMed ID: 1380686
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Challenges to behavioral research in oncology.
    Mock V; Hill MN; Dienemann JA; Grimm PM; Shivnan JC
    Cancer Pract; 1996; 4(5):267-73. PubMed ID: 9004573
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Workshop/conference report on EMA draft guideline on validation of bioanalytical methods.
    Blume H; Brendel E; Brudny-Klöppel M; Grebe S; Lausecker B; Rohde G; Siethoff C
    Eur J Pharm Sci; 2011 Feb; 42(3):300-5. PubMed ID: 21185936
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Growth Hormone Research Society perspective on the development of long-acting growth hormone preparations.
    Christiansen JS; Backeljauw PF; Bidlingmaier M; Biller BM; Boguszewski MC; Casanueva FF; Chanson P; Chatelain P; Choong CS; Clemmons DR; Cohen LE; Cohen P; Frystyk J; Grimberg A; Hasegawa Y; Haymond MW; Ho K; Hoffman AR; Holly JM; Horikawa R; Höybye C; Jorgensen JO; Johannsson G; Juul A; Katznelson L; Kopchick JJ; Lee KO; Lee KW; Luo X; Melmed S; Miller BS; Misra M; Popovic V; Rosenfeld RG; Ross J; Ross RJ; Saenger P; Strasburger CJ; Thorner MO; Werner H; Yuen K
    Eur J Endocrinol; 2016 Jun; 174(6):C1-8. PubMed ID: 27009113
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Risk assessment practice for essential metals.
    Meek ME; Levy LS; Beck BD; Danzeisen R; Donohue JM; Arnold IM; Krewski D
    J Toxicol Environ Health A; 2010; 73(2):253-60. PubMed ID: 20077295
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Suggested statistical standards for NTT manuscripts: notes from two of your reviewers.
    Bookstein FL; Sampson PD
    Neurotoxicol Teratol; 2005; 27(3):407-15. PubMed ID: 15939201
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A critical view of the utility of positive controls in a test battery.
    Tachibana T
    Neurobehav Toxicol Teratol; 1984; 6(2):155-9. PubMed ID: 6472560
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Analyses of neurobehavioral screening data: dose-time-response modeling of continuous outcomes.
    Zhu Y; Wessel MR; Liu T; Moser VC
    Regul Toxicol Pharmacol; 2005 Apr; 41(3):240-55. PubMed ID: 15748798
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Comments from the Behavioral Teratology Committee of the Japanese Teratology Society on OECD guideline for the testing of chemicals, proposal for a new guideline 426, developmental neurotoxicity study, draft document (September 2003).
    Fukui Y; Ema M; Fujiwara M; Higuchi H; Inouye M; Iwase T; Kihara T; Nishimura T; Oi A; Ooshima Y; Otani H; Shinomiya M; Sugioka K; Yamano T; Yamashita KH; Tanimura T;
    Congenit Anom (Kyoto); 2004 Sep; 44(3):172-7. PubMed ID: 15327486
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Practical considerations in establishing valid and sensitive neurobehavioral test methods.
    Tilson HA
    Zentralbl Bakteriol Mikrobiol Hyg B Umwelthyg Krankenhaushyg Arbeitshyg Prav Med; 1987 Oct; 185(1-2):10-5. PubMed ID: 3124371
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Are acute toxicity testing and the three Rs rule reconcilable? Example of the lethal dose 50 determination].
    Dorandeu F; Lallement G
    Ann Pharm Fr; 2003 Nov; 61(6):399-411. PubMed ID: 14639192
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Toward better research practice--shortcomings decreasing the significance of epidemiological studies in the toxicological field.
    Meyer-Baron M; Schäper M; van Thriel C
    Neurotoxicology; 2014 Dec; 45():238-46. PubMed ID: 24657405
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Value of juvenile animal studies.
    Leconte I; Bailey G; Davis-Bruno K; Hew KW; Kim J; Silva Lima B; Liminga U; Moffit J; De Schaepdrijver L; Schmitt G; Tassinari M; Thompson K; Hurtt M
    Birth Defects Res B Dev Reprod Toxicol; 2011 Aug; 92(4):292-303. PubMed ID: 22623020
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Test guideline. Behavioral toxicity testing in animal experiments according to section 9, para. 1, No. 2 of the Chemicals Act (Chemikaliengesetz) of the Federal Republic of Germany.
    Spielmann H; Bomhard E; Lehr E; Leuschner F; Portig J; Schlatterer B; Stötzer H
    Zentralbl Bakteriol Mikrobiol Hyg B Umwelthyg Krankenhaushyg Arbeitshyg Prav Med; 1987 Oct; 185(1-2):16-20. PubMed ID: 3124378
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Dose-dependent transitions in mechanisms of toxicity.
    Slikker W; Andersen ME; Bogdanffy MS; Bus JS; Cohen SD; Conolly RB; David RM; Doerrer NG; Dorman DC; Gaylor DW; Hattis D; Rogers JM; Setzer RW; Swenberg JA; Wallace K
    Toxicol Appl Pharmacol; 2004 Dec; 201(3):203-25. PubMed ID: 15582645
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Nonclinical strategy considerations for safety pharmacology: evaluation of biopharmaceuticals.
    Vargas HM; Amouzadeh HR; Engwall MJ
    Expert Opin Drug Saf; 2013 Jan; 12(1):91-102. PubMed ID: 23170873
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.